These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23977248)

  • 1. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
    Billeskov R; Christensen JP; Aagaard C; Andersen P; Dietrich J
    PLoS One; 2013; 8(8):e72185. PubMed ID: 23977248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
    Elvang T; Christensen JP; Billeskov R; Thi Kim Thanh Hoang T; Holst P; Thomsen AR; Andersen P; Dietrich J
    PLoS One; 2009; 4(4):e5139. PubMed ID: 19357780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis.
    You Q; Jiang C; Wu Y; Yu X; Chen Y; Zhang X; Wei W; Wang Y; Tang Z; Jiang D; Wu Y; Wang C; Meng X; Zhao X; Kong W
    Scand J Immunol; 2012 Jan; 75(1):77-84. PubMed ID: 21916923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice.
    Stylianou E; Diogo GR; Pepponi I; van Dolleweerd C; Arias MA; Locht C; Rider CC; Sibley L; Cutting SM; Loxley A; Ma JK; Reljic R
    Eur J Immunol; 2014 Feb; 44(2):440-9. PubMed ID: 24214530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.
    Siddiqui KF; Amir M; Khan N; Rama Krishna G; Sheikh JA; Rajagopal K; Agrewala JN
    Clin Exp Immunol; 2015 Aug; 181(2):286-96. PubMed ID: 25845290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological characterization of chimeras of high specificity antigens from Mycobacterium tuberculosis H37Rv.
    Fatma F; Tripathi DK; Srivastava M; Srivastava KK; Arora A
    Tuberculosis (Edinb); 2021 Mar; 127():102054. PubMed ID: 33550109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
    You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
    Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
    Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
    Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multistage protein subunit vaccine as BCG-booster confers protection against Mycobacterium tuberculosis infection in murine models.
    Chen Z; Zhang Y; Wu J; Xu J; Hu Z; Fan XY
    Int Immunopharmacol; 2024 Sep; 139():112811. PubMed ID: 39068754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
    Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
    Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.
    Baldwin SL; Ching LK; Pine SO; Moutaftsi M; Lucas E; Vallur A; Orr MT; Bertholet S; Reed SG; Coler RN
    J Immunol; 2013 Sep; 191(5):2514-2525. PubMed ID: 23904160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis.
    Liang J; Teng X; Yuan X; Zhang Y; Shi C; Yue T; Zhou L; Li J; Fan X
    Mol Immunol; 2015 Aug; 66(2):392-401. PubMed ID: 25974877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.